Summit Therapeutics
- Country
- 🇬🇧United Kingdom
- Ownership
- -
- Employees
- 105
- Market Cap
- $9.7B
- Introduction
Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.
Summit Therapeutics' Ivonescimab Shows Promising Results in Phase 3 NSCLC Trial
Summit Therapeutics reported statistically significant improvement in progression-free survival for ivonescimab plus chemotherapy versus BeiGene's Tevimbra combination in advanced squamous non-small cell lung cancer.
Akeso Secures FDA Approval for Novel Cancer Drug While Partner Summit Therapeutics Faces Sharp Stock Decline
Akeso has received FDA approval for its first internally developed cancer therapeutic, marking a significant milestone for the Chinese biopharmaceutical company's expansion into the US market.
Summit's Ivonescimab Shows Promise in Phase III Trial Against Established Lung Cancer Therapies
Summit Therapeutics and Akeso's bispecific antibody ivonescimab demonstrated superior progression-free survival compared to BeiGene's tislelizumab in squamous non-small cell lung cancer patients, adding to previous positive results against Merck's Keytruda.
Akeso Reports Positive Phase 3 Results for Ivonescimab in Lung Cancer, Building on Recent FDA Approval Success
Akeso announced positive Phase 3 results for ivonescimab, a novel PD-1/VEGF bispecific antibody, demonstrating superior tumor progression control when combined with chemotherapy compared to PD-1 inhibitor plus chemotherapy in lung cancer patients.
BioNTech's BNT327 Shows Promising 85% Response Rate in First-Line Treatment for Extensive-Stage SCLC
BNT327, a bispecific antibody targeting both PD-L1 and VEGF-A, demonstrated an 85.4% confirmed response rate when combined with chemotherapy in extensive-stage small cell lung cancer patients.
Summit Therapeutics Partners with Pfizer to Evaluate Novel Cancer Drug Combination Amid Financial Losses
Summit Therapeutics announces strategic collaboration with Pfizer to evaluate their cancer drug ivonescimab in combination with Pfizer's antibody drug conjugates for solid tumor treatment.
Summit and Pfizer Partner to Evaluate Novel Cancer Therapy Combinations with Ivonescimab
Summit Therapeutics and Pfizer have established a clinical trial collaboration to test ivonescimab, a PD-1/VEGF bispecific antibody, in combination with Pfizer's antibody drug conjugates for multiple solid tumors.
Akeso Completes Patient Enrollment in Phase III Trial Comparing Ivonescimab for First-Line Squamous NSCLC Treatment
Akeso has completed enrollment for the HARMONi-6 Phase III trial comparing ivonescimab plus chemotherapy to tislelizumab plus chemotherapy for first-line squamous non-small cell lung cancer treatment.
Summit's Ivonescimab Emerges as Potential Keytruda Challenger in Major Cancer Treatment Breakthrough
Summit Therapeutics' ivonescimab demonstrated superior performance against Merck's Keytruda in clinical trials, marking a significant advancement in cancer immunotherapy development.
Summit Therapeutics Advances Ivonescimab Program with Pfizer Collaboration and Phase III Trial Progress in NSCLC
Summit Therapeutics collaborates with Pfizer to evaluate ivonescimab with Pfizer's ADCs across solid tumors, aiming to improve therapeutic combinations.